Renfeng Guo
Founder at INFLARX N.V.
Net worth: 3 M $ as of 30/03/2024
Profile
Renfeng Guo founded InflaRx GmbH in 2007, where he worked as Chief Scientific Officer from 2009 to 2012 and InflaRx NV in 2007, where he is working as Executive Director & Chief Scientific Officer from 2007.
Dr. Guo also formerly worked at the University of Michigan, as Associate Professor.
Dr. Guo received his doctorate degree from Norman Bethune Medical University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INFLARX N.V.
2.99% | 30/12/2023 | 1,762,144 ( 2.99% ) | 3 M $ | 30/03/2024 |
Renfeng Guo active positions
| Companies | Position | Start |
|---|---|---|
| INFLARX N.V. | Founder | 30/11/2007 |
Former positions of Renfeng Guo
| Companies | Position | End |
|---|---|---|
| University of Michigan | Corporate Officer/Principal | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Founder | - |
Training of Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Private companies | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
- Stock Market
- Insiders
- Renfeng Guo
